Literature DB >> 2572901

Hypocholesterolaemia and increased elimination of low-density lipoproteins in metastatic cancer of the prostate.

P Henriksson1, M Eriksson, S Ericsson, M Rudling, R Stege, L Berglund, B Angelin.   

Abstract

To study the influence of tumour mass on lipid metabolism, the lipoprotein pattern in untreated patients with newly diagnosed cancer of the prostate was examined. Total cholesterol levels were reduced in patients with evidence of metastasis (n = 30) compared with those without metastasis (n = 73). Since the major fraction of serum cholesterol is contained in low-density lipoproteins (LDL), turnover of LDL was studied in detail in 8 patients compared with 12 age-matched healthy men. LDL were cleared faster in the 3 patients with metastatic disease than in the patients without metastasis and in controls, indicating faster catabolism of LDL. Thus in prostatic cancer an increased tumour burden is associated with increased elimination of LDL, which contributes to reduced serum cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572901     DOI: 10.1016/s0140-6736(89)91790-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  17 in total

1.  Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins.

Authors:  Mohana Roy; Hsing-Jien Kung; Paramita M Ghosh
Journal:  Am J Cancer Res       Date:  2011-03-28       Impact factor: 6.166

2.  Drug-targeting in combined cancer chemotherapy: tumor growth inhibition in mice by association of paclitaxel and etoposide with a cholesterol-rich nanoemulsion.

Authors:  Iara F Kretzer; Durvanei A Maria; Raul C Maranhão
Journal:  Cell Oncol (Dordr)       Date:  2012-10-03       Impact factor: 6.730

3.  Low density lipoprotein receptors and polyamine levels in human colorectal adenocarcinoma.

Authors:  M Notarnicola; M Linsalata; M G Caruso; A Cavallini; A Di Leo
Journal:  J Gastroenterol       Date:  1995-12       Impact factor: 7.527

4.  Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.

Authors:  Jia Gu; Neng Zhu; Hong-Fang Li; Tan-Jun Zhao; Chan-Juan Zhang; Duan-Fang Liao; Li Qin
Journal:  Cell Oncol (Dordr)       Date:  2022-07-22       Impact factor: 7.051

5.  Serum lipids and left-sided adenomas of the large bowel: an extended study of self-defense officials in Japan.

Authors:  S Kono; K Imanishi; K Shinchi; F Yanai
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

6.  Prospective associations between serum biomarkers of lipid metabolism and overall, breast and prostate cancer risk.

Authors:  Mathilde His; Laurent Zelek; Mélanie Deschasaux; Camille Pouchieu; Emmanuelle Kesse-Guyot; Serge Hercberg; Pilar Galan; Paule Latino-Martel; Jacques Blacher; Mathilde Touvier
Journal:  Eur J Epidemiol       Date:  2014-02-13       Impact factor: 8.082

7.  Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy.

Authors:  S Vitols; B Angelin; S Ericsson; G Gahrton; G Juliusson; M Masquelier; C Paul; C Peterson; M Rudling; K Söderberg-Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

8.  Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies.

Authors:  M R Law; S G Thompson
Journal:  Cancer Causes Control       Date:  1991-07       Impact factor: 2.506

9.  Tumor-Induced Hyperlipidemia Contributes to Tumor Growth.

Authors:  Jianfeng Huang; Lena Li; Jihong Lian; Silvia Schauer; Paul W Vesely; Dagmar Kratky; Gerald Hoefler; Richard Lehner
Journal:  Cell Rep       Date:  2016-03-31       Impact factor: 9.423

10.  Effect of neoadjuvant chemotherapy on low-density lipoprotein (LDL) receptor and LDL receptor-related protein 1 (LRP-1) receptor in locally advanced breast cancer.

Authors:  L A Pires; R Hegg; F R Freitas; E R Tavares; C P Almeida; E C Baracat; R C Maranhão
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.